Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 239

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 239
---
 decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an
                                            existing clinical trial;

85

●adverse
                                            regulatory decisions, including failure to receive regulatory approval of our drug to market
                                            for our product candidates;

●adverse
                                            developments concerning our manufacturers;

●our
                                            inability to obtain adequate product supply for any approved drug or inability to do so at
                                            acceptable prices;

●our
                                            inability to establish collaborations, if needed;

●our
                                            failure to commercialize our product candidates;

●additions
                                            or departures of key scientific or management personnel;

●unanticipated
                                            serious safety concerns related to the use of our product candidates;

●introduction
                                            of new drugs by our competitors;

●announcements
                                            of significant acquisitions, strategic partnerships, joint ventures or capital commitments
                                            by us or our competitors;

●any
                                            significant change in our management;

●our
                                            ability to effectively manage our growth;

●the
                                            size and growth of our initial target markets;

●actual
                                            or anticipated variations in quarterly operating results;

●our
                                            cash position;

●our
                                            failure to meet the estimates and projections of the investment community or that we may
                                            otherwise provide to the public;

●the
                                            public’s response to press releases or other public announcements by us or third parties,
                                            including our filings with the SEC;

●publication
                                            of research reports about us or our industry, or microbiome therapies in particular, or positive
                                            or negative recommendations or withdrawal of research coverage by securities analysts;

●guidance,
                                            if any, that we provide to the public, any changes in this guidance or our failure to meet
                                            this guidance;

●changes
                                            in the market valuations of similar companies;

●overall
                                            performance of the equity markets;

●sales
                                            of our Common Stock by us or our stockholders, in the future;

●trading
                                            volume of our Common Stock;

●investor
                                            perceptions of the investment opportunity associated with our Common Stock relative to other
                                            investment alternatives;

86

●actions
                                            by institutional or activist stockholders;

●change
                                            in accounting standards, policies, guidelines, interpretations or principles;

●ineffectiveness
                                            of our internal controls;

●disputes
                                            or other developments relating to proprietary rights, including patents, litigation matters
                                            and our ability to obtain patent protection for our technologies;

●significant
                                            lawsuits, including patent or stockholder